Role of serum alpha-klotho and fgf23 in cardiovascular calcification


L.I. Rudenko, M.M. Batjushin, A.A. Kastanajan, B.I. Vorob'ev, I.V. Sarvilina

1SBEI HPE «Rostov State Medical University» of the MH of the RF, of the Department of Internal Medicine and Basic Physiology, Rostov-on-Don 2LLC “Medical Center “NOVOMEDICINA”
Aim: To determine the association between the level of alpha-Klotho, FGF-23 and the presence of structural and functional cardiovascular abnormalities in dialysis patients.
Materials and Methods: Eighty-three patients from two dialysis centers. Initial assessment included medical history, anthropometric measures, laboratory tests, echocardiography and plain abdominal X-ray.
Results: Serum levels of alpha-Klotho and FGF-23 were measured in a cohort of dialysis patients. Reduction of alpha-Klotho concentrations correlated with the left ventricular hypertrophy of (LVH) as assessed by echocardiography and with the abdominal aorta calcification as assessed from abdominal x-ray in lateral view. Changes in the levels of FGF-23 have not shown a similar correlation.
Conclusion: Alpha-Klotho can be used as a marker for cardiovascular disease in dialysis patients.

Literature


  1. Levey A.S., Atkins R., Coresh J. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes // Kidney Int. – 2007. – Vol. 72. – P. 247–259.
  2. U.S. Renal Data System. Bethesda, MD: 2010. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
  3. Mann J.F., Gerstein H.C., Pogue J. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial // Ann Intern Med. – 2001. – Vol. 134. – P. 629–636.
  4. Shimada T., Hasegawa H., Yamazaki Y. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis // J Bone Miner Res. – 2004. – Vol. 19. – P. 429–435
  5. Pavik I., Jaeger P., Ebner L. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study // Nephrol Dial Transplant. – 2013. – Vol. 28. – P. 352–359.
  6. Kuro-o M. Klotho in health and disease // Curr Opin Nephrol Hypertens. – 2012. – Vol. 21. – P. 362–368.
  7. Lim K., Lu T.S., Molostvov G. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23 // Circulation. – 2012. – Vol. 125. – P. 2243–2255
  8. Imura A., Iwano A., Tohyama O. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane // FEBS Lett. – 2004. – Vol. 565. – P. 143–147.
  9. Hu M.C., Shi M., Zhang J. Klotho deficiency causes vascular calcification in chronic kidney disease // J Am Soc Nephrol. – 2011. – Vol. 22. – P. 124–136.
  10. Chen H.C., Lim L.M., Chang J.M. Save life and improve quality: report from the 5th Congress of International Society for Hemodialysis // Hemodial Int. – 2014 Jan. – Vol. 18(1). – P. 163–71.
  11. Urena Torres P., Friedlander G., de Vernejoul M.C. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients // Kidney Int. – 2008 Jan. – Vol. 73(1). – P. 102–107
  12. Miao L.-Y., Zhu B. Effects of three blood purification methods on serum fibroblast growth factor-23 clearance in patients with hyperphosphatemia undergoing maintenance hemodialysis // Exp Ther Med. – 2014 Apr. – Vol. 7(4). – P. 947–952
  13. Nasrallah M.M., El-Shehaby A.R., Salem M.M. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients // Nephrol Dial Transplant. – 2010 Aug. – Vol. 25(8). – P. 2679–85.
  14. M.M. NasrAllah, A.R. El-Shehaby. The Association between Fibroblast Growth Factor-23 and Vascular Calcification Is Mitigated by Inflammation Markers // Nephron Extra. – 2013 Jan-Dec. – Vol. 3(1). – P. 106–112
  15. Литвинов А.С., Батюшин М.М., Литвинова Л.И. (Руденко). Проблемы биосовместимости диализной терапии // Нефрология. – 2013. – Т.17. – № 5. – C. 27–34.
  16. Yamamoto M., Clark J.D., Pastor J.V. Regulation of oxidative stress by the anti-aging hormone klotho // J Biol Chem. – 2005. – Vol. 280. – P. 38029–38034.
  17. Olivecrona S., Gunnarsson I. FGF23, Albuminuria, and Disease Progression in Patients with Chronic IgA Nephropathy // Clin J Am Soc Nephrol. – 2012. – May; Vol. 7(5). – P. 727–734.
  18. Kuro-o M. Klotho in health and disease // Curr Opin Nephrol Hypertens. – 2012. – Vol. 21. – P. 362–368.
  19. Dai B., David V., Martin A. A Comparative Transcriptome Analysis Identifying FGF23 Regulated Genes in the Kidney of a Mouse CKD Model // PLoS One. – 2012. – Vol. 7. – P. 44161.
  20. Urena Torres P., Friedlander G., de Vernejoul M.C. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients // Kidney Int. – 2008 Jan. – Vol. 73(1). – P. 102–107.
  21. Miao L.-Y., Zhu B. Effects of three blood purification methods on serum fibroblast growth factor-23 clearance in patients with hyperphosphatemia undergoing maintenance hemodialysis // Exp Ther Med. – 2014. – Apr; Vol. 7(4). – P. 947–952.
  22. Imura A., Iwano A., Tohyama O. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane // FEBS Lett. – 2004. – Vol. 565. – P. 143–147.
  23. Hu M.C., Shi M., Zhang J. Klotho deficiency causes vascular calcification in chronic kidney disease // J Am Soc Nephrol. – 2011. – Vol. 22. – P. 124–136.
  24. Батюшин М.М., Галушкин А.А., Руденко Л.И. Особенности течения хронической почечной недостаточности, осложненной вторичным гиперпаратиреозом // Медицинский вестник Юга России. – 2012. – № 1. – C. 74–76.


About the Autors


Author information:
L.I. Rudenko - Doctoral Student of the Department of Internal Medicine and Basic Physiology #2, Nephrologist of the Nephrology Department of SBEI HPE “RostSMU” of the MH of the RF; e-mail: rudenko.liliya@mail.ru
M.M. Batjushin – Ph.D., Prof. of the Department of Internal Medicine and Basic Physiology #2 of SBEI HPE “RostSMU” of the MH of the RF
A.A. Kastanajan – Ph.D., Prof., Head of the Department of Internal Medicine and Basic Physiology #2 of SBEI HPE “RostSMU” of the MH of the RF
B.I. Vorob'ev - Ph.D., Prof. of the Department of Internal Medicine and Basic Physiology #2 of SBEI HPE “RostSMU” of the MH of the RF
I.V. Sarvilina – Director of LLC “Medical Center “NOVOMEDICINA”


Similar Articles


Бионика Медиа